Photo medecin

Professeur BONNEFOI Hervé

PUPH
Spécialité:
+33 5 56 33 32 79

Professeur des Universités – Praticien hospitalier (PU-­‐PH) Université de Bordeaux

Institut Bergonié INSERM U1218 Bordeaux, France

 

Hervé Bonnefoi est professeur d’oncologie à l’Université de Bordeaux et praticien hospitalier à l’Institut Bergonié. Il est privat-docent de l’université de Genève.

Le Pr Bonnefoi a fait ses études à la Faculté de médecine de Grenoble. Il a ensuite complété sa formation d’oncologue médical à l’Université de Genève et au Royal Marsden Hospital à Londres.

Son programme de recherche du Professeur concerne deux domaines. Il s’intéresse tout d’abord au traitement neoadjuvant et post-­‐neoadjuvant des cancers du sein avec en particulier la recherche d’anomalies génomiques ciblables par des traitements spécifiques; son objectif est d’identifier des mécanismes de résistance aux traitements hormonaux afin d’éviter leur apparition. Par ailleurs, il porte un intérêt tout particulier à un sous-­‐type de cancers du sein dénommé apocrine moléculaire. Ses recherches concernant ce sous-­‐type de cancer du sein vont du laboratoire avec le développement de modèles précliniques, jusqu’à la clinique avec l’évaluation de nouveaux traitements auprès des patientes. Le programme de recherche du Pr Bonnefoi est mené en collaboration avec avec l’équipe du Pr Richard Iggo (Unité INSERM U1218 située dans l’Institut Bergonié); le Karolinska Institute à Stockholm; le Sanger Institute à Cambridge; et plusieurs groupes de recherche clinique académiques (EORTC: European Organisation for Research and Treatment of Cancer; IBCSG: International Breast Cancer Study Group; UCBG: Intergroupe français de recherche sur le cancer du sein).

Le Pr Bonnefoi est membre du Comité scientifique de la Conférence Européenne sur le cancer du sein (EBCC) depuis 2000, du Comité scientifique de la Société Européenne de Cancérologie (ESMO) depuis 2016, et du panel des experts du Consensus de St Gall depuis 2011. Il a été membre de du Comité scientifique du Congrès de la Société Américaine d’Oncologie (ASCO) de 2009 à 2011. Il a été président du groupe sein de l’EORTC et de l’intergroupe français de recherche sur le cancer du sein (UCBG). Il est membre du comité de direction de ces deux groupes.

Il est reviewer pour plusieurs journaux scientifiques à comité éditorial et auteur (ou co-auteur) de nombreux articles publiés dans les journaux suivants : Annals of Oncology, Breast Cancer Research, Breast Cancer Research and Treatment, European Journal of Cancer, Lancet, Lancet Oncology, Nature Medicine, New England Journal of Medicine et Oncogene.

Selection des 15 publications principales depuis 2005

1. Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L’Haridon T, Cottu P, Abadie-­‐Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges M, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A phase II trial of abiraterone acetate plus prednisone in patients with triple-­‐negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-­‐1). Ann Oncol 2016;27:812-­‐8

2. Richard E, Grellety T, Velasco V, MacGrogan G, Bonnefoi H, Iggo R. The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tum J Pathol 2016 (in press)

3. Fei F, Messina C, Slaets L, Chakiba C, Camerom D, Bogaerts J, Bonnefoi H. Tumour size is the only predictive factor of distant recurrence after pathological complete response (pCR) to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-­‐study of EORTC 10994/BIG-­‐001 Phase III Eur J Cancer 2015; 51:301-­‐9

4. Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-­‐Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-­‐Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina C, Slaets L, Cameron D. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab,  or both followed by an anthracycline  based chemotherapy  in HER2-­‐positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol 2015; 26:325-­‐32

5. Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, André F. Precision medicine for metastatic breast cancer-­‐limitations and solutions. Nat Rev Clin Oncol 2015;12:693-­‐704

6. Francis P, Regan M, Fleming G, Láng I, Eva Ciruelos E, Bellet M, Bonnefoi H, Climent M, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer E, Rabaglio-­‐ Poretti M, Maibach R, Ruepp B, Giobbie-­‐Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Function Suppression in Premenopausal Breast Cancer. N Engl J Med 2015;372:436-­‐46

7. Francis P, Regan M, Fleming G, Láng I, Eva Ciruelos E, Bellet M, Bonnefoi H, Climent M, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer E, Rabaglio-­‐ Poretti M, Maibach R, Ruepp B, Giobbie-­‐Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Function Suppression in Premenopausal Breast Cancer. N Engl J Med 2015;372:436-­‐46

8. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer CE, , Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-­‐Poretti M, Maibach R, Ruepp B, Giobbie-­‐Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med 2014

9. Bonnefoi H, Litiere S, Piccart M, Macgrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmstrom P, Werutsky G, Bogaerts J, Bergh J, Cameron DA. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-­‐step approach analyses from the EORTC 10994/BIG 1-­‐00 phase III trial. Ann Oncol 2014 ; 6: 1128-­‐36

10. André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-­‐Triki M, Lacroix L, Cohen P, Gentien D, Adelaide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonneterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H. Array CGH and DNA sequencing for treatment decision in metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014 ; 15: 267-­‐274

11. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, , Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological Complete Response in Breast Cancer: CTNeoBC Pooled-­‐Analysis. Lancet 2014

12. Iggo R, Rudewicz J, Monceau E, Sevenet N, Bergh J, Sjoblom T, Bonnefoi H. Validation of a yeast functional assay for p53 mutations using clonal sequencing. J Pathol 2013 ; 231 : 441-­‐8

13. Bonnefoi H, Piccart M, Bogaerts J et al. TP53 status for prediction of sensitivity to taxane versus non-­‐taxane neoadjuvant chemotherapy  in breast cancer (EORTC 10994/BIG 1-­‐00): a randomised phase 3 trial. Lancet Oncology 2011; 12:527-­‐539

14. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M. A stroma-­‐ related gene signature predicts resistance to neoadjuvant chemotherapy  in breast cancer. Nat Med

2009;15(1):68-­‐74

15. Farmer P, Bonnefoi H, Becette V, Tubiana-­‐Hulin M, Fumoleau P, Larsimont D, MacGrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification  of molecular apocrine breast tumors by microarray analysis. Oncogene 2005; 24:4660-­‐71

English version

Hervé Bonnefoi, MD, is a professor of Medical Oncology at the University of Bordeaux, and consultant at the Bergonié Cancer Institute in Bordeaux. He obtained a privat-­‐docent in Geneva Medical University.

Professor Bonnefoi received his medical degree from the University of Grenoble Medical School in Grenoble, France, and completed further training at the University of Geneva, Switzerland; and the Royal Marsden Hospital in London, United-­‐Kingdom.

His research interests focus on the neoadjuvant and post-­‐neoadjuvant treatment of breast cancer as well as the identification of targetable genomic aberrations in patients whose tumors did not achieve a pathological complete response after neoadjuvant chemotherapy; his aim is to identify mechanisms of resistance to hormonal therapy and to develop preclinical breast cancer models including molecular apocrine tumors. These studies are being conducted in collaboration with Prof. Richard Iggo within the INSERM unit located in Bergonié Institute and with the Karolinska Institute in Stockholm, Sweden; the Sanger Institute in Cambridge, United-­‐Kingdom; and several academic research groups (EORTC: European Organisation for Research and Treatment of Cancer; IBCSG: International Breast Cancer Study Group; UCBG: Unicancer Breast Intergroup).

Professor Bonnefoi is a member of the European Breast Cancer Conference (EBCC) Scientific Committee (since 2000), European Society of Medical Oncology (ESMO Scientific) Committee (since

2016), and St Gallen breast cancer Consensus Meeting expert panel (since 2011). He was a member of the American Society of Clinical Oncology (ASCO) Scientific Committee (2009-­‐2011; track-­‐leader in 2011) and Educational Program Committee (2011). He is a past chair of the European EORTC Breast Cancer Group and the UNICANCER French Breast Cancer Intergroup (UCBG). He is a member of the steering committee of these two research groups dedicated to breast cancer.

A reviewer for several peer-­‐reviewed journals, Professor Bonnefoi is author or coauthor of numerous articles that have appeared in Annals of Oncology, Breast Cancer Research, Breast Cancer Research and Treatment, European Journal of Cancer, Lancet, Lancet Oncology, Nature Medicine, New England Journal of Medicine, and Oncogene among others.

 

Selection of 15 publications since 2005

1. Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L’Haridon T, Cottu P, Abadie-­‐Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges M, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A phase II trial of abiraterone acetate plus prednisone in patients with triple-­‐negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-­‐1). Ann Oncol 2016;27:812-­‐8

2. Richard E, Grellety T, Velasco V, MacGrogan G, Bonnefoi H, Iggo R. The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours. J Pathol 2016 (in press)

3. Fei F, Messina C, Slaets L, Chakiba C, Camerom D, Bogaerts J, Bonnefoi H. Tumour size is the only predictive factor of distant recurrence after pathological complete response (pCR) to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-­‐study of EORTC 10994/BIG-­‐001 Phase III Trial. Eur J Cancer 2015; 51:301-­‐9

4. Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-­‐Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-­‐Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina C, Slaets L, Cameron D. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-­‐positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol. 2015; 26:325-­‐32

5. Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, André F. Precision medicine for metastatic breast cancer-­‐limitations and solutions. Nat Rev Clin Oncol 2015;12:693-­‐704

6. Francis P, Regan M, Fleming G, Láng I, Eva Ciruelos E, Bellet M, Bonnefoi H, Climent M, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer E, Rabaglio-­‐ Poretti M, Maibach R, Ruepp B, Giobbie-­‐Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Function Suppression in Premenopausal Breast Cancer. N Engl J Med 2015;372:436-­‐46

7. Francis P, Regan M, Fleming G, Láng I, Eva Ciruelos E, Bellet M, Bonnefoi H, Climent M, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer E, Rabaglio-­‐ Poretti M, Maibach R, Ruepp B, Giobbie-­‐Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Function Suppression in Premenopausal Breast Cancer. N Engl J Med 2015;372:436-­‐46

8. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer CE, , Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-­‐Poretti M, Maibach R, Ruepp B, Giobbie-­‐Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med 2014

9. Bonnefoi H, Litiere S, Piccart M, Macgrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmstrom P, Werutsky G, Bogaerts J, Bergh J, Cameron DA. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-­‐step approach analyses from the EORTC 10994/BIG 1-­‐00 phase III trial. Ann Oncol 2014 ; 6: 1128-­‐36

10. André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-­‐Triki M, Lacroix L, Cohen P, Gentien D, Adelaide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonneterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H. Array CGH and DNA sequencing for treatment decision in metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014 ; 15: 267-­‐274  

11. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, , Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological Complete Response in Breast Cancer: CTNeoBC Pooled-­‐Analysis. Lancet 2014

12. Iggo R, Rudewicz J, Monceau E, Sevenet N, Bergh J, Sjoblom T, Bonnefoi H. Validation of a yeast functional assay for p53 mutations using clonal sequencing. J Pathol 2013 ; 231 : 441-­‐8

13. Bonnefoi H, Piccart M, Bogaerts J et al. TP53 status for prediction of sensitivity to taxane versus non-­‐taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-­‐00): a randomised phase 3 trial. Lancet Oncology 2011; 12:527-­‐539

14. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M. A stroma-­‐ related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009;15(1):68-­‐74

15. Farmer P, Bonnefoi H, Becette V, Tubiana-­‐Hulin M, Fumoleau P, Larsimont D, MacGrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumors by microarray analysis. Oncogene 2005; 24:4660-­‐71